Schellekens AF - Search Results

1

Psilocybin for treating substance use disorders?

de Veen BT, Schellekens AF, Verheij MM, Homberg JR. de Veen BT, et al. Among authors: schellekens af. Expert Rev Neurother. 2017 Feb;17(2):203-212. doi: 10.1080/14737175.2016.1220834. Epub 2016 Aug 12. Expert Rev Neurother. 2017. PMID: 27684102 Review.

2

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR. Belgers M, et al. Among authors: schellekens af. Transl Psychiatry. 2016 May 31;6(5):e826. doi: 10.1038/tp.2016.71. Transl Psychiatry. 2016. PMID: 27244235 Free PMC article. Review.

3

Substance Misuse Education for Physicians: Why Older People are Important.

De Jong CA, Goodair C, Crome I, Jokubonis D, El-Guebaly N, Dom G, Schellekens A, Broers B, Subata E, Welle-Strand GK, Luycks L, Wolters M, Schoof T. De Jong CA, et al. Yale J Biol Med. 2016 Mar 24;89(1):97-103. eCollection 2016 Mar. Yale J Biol Med. 2016. PMID: 27505022 Free PMC article. Review.

4

Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.

Van de Wijer L, Schellekens AFA, Burger DM, Homberg JR, de Mast Q, van der Ven AJAM. Van de Wijer L, et al. Lancet Infect Dis. 2016 May;16(5):e76-e81. doi: 10.1016/S1473-3099(16)00117-1. Epub 2016 Apr 18. Lancet Infect Dis. 2016. PMID: 27599655 Review.

5

The role of the habenula in the transition from reward to misery in substance use and mood disorders.

Batalla A, Homberg JR, Lipina TV, Sescousse G, Luijten M, Ivanova SA, Schellekens AFA, Loonen AJM. Batalla A, et al. Neurosci Biobehav Rev. 2017 Sep;80:276-285. doi: 10.1016/j.neubiorev.2017.03.019. Epub 2017 May 30. Neurosci Biobehav Rev. 2017. PMID: 28576510 Review.

6

Are There Differences in Disruptions of Reward Processing Between Substance Use Disorder and Gambling Disorder?-Reply.

Schellekens AF, Luijten M, Sescousse G. Schellekens AF, et al. JAMA Psychiatry. 2017 Jul 1;74(7):760-761. doi: 10.1001/jamapsychiatry.2017.1054. JAMA Psychiatry. 2017. PMID: 28593251 No abstract available.

7

Relating addiction and psychiatric disorders.

Vink JM, Schellekens A. Vink JM, et al. Science. 2018 Sep 28;361(6409):1323-1324. doi: 10.1126/science.aav3928. Science. 2018. PMID: 30262491 No abstract available.

8

Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model.

van de Wijer L, Garcia LP, Hanswijk SI, Rando J, Middelman A, Ter Heine R, Mast Q, Martens GJM, van der Ven AJAM, Kolk SM, Schellekens AFA, Homberg JR. van de Wijer L, et al. Transl Psychiatry. 2019 Feb 11;9(1):84. doi: 10.1038/s41398-019-0420-y. Transl Psychiatry. 2019. PMID: 30745561 Free PMC article.

9

Perinatal exposure of rats to the HIV drug efavirenz affects medial prefrontal cortex cytoarchitecture.

Garcia LP, Van de Wijer L, Hanswijk SI, Rando J, Witteveen JS, Middelman A, Ter Heine R, de Mast Q, Martens GJM, van der Ven AJAM, Schellekens AFA, Homberg JR, Kolk SM. Garcia LP, et al. Biochem Pharmacol. 2020 Aug;178:114050. doi: 10.1016/j.bcp.2020.114050. Epub 2020 May 22. Biochem Pharmacol. 2020. PMID: 32446887 Free article.

10

Characterization of the GHB Withdrawal Syndrome.

Wolf CJH, Beurmanjer H, Dijkstra BAG, Geerlings AC, Spoelder M, Homberg JR, Schellekens AFA. Wolf CJH, et al. J Clin Med. 2021 May 26;10(11):2333. doi: 10.3390/jcm10112333. J Clin Med. 2021. PMID: 34073640 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page